2025-09-04 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided.  The report is structured to present key figures first, followed by analysis and context.

**Report on Johnson & Johnson (JNJ)**

**1. Performance Overview**

*   **Ticker:** JNJ
*   **Company Description:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

**1.1. Relative Performance:**

*   **JNJ Cumulative Return:** 29.81%
*   **S&P 500 (VOO) Cumulative Return:** 99.17%
*   **Performance Spread:** -73.0
*   **Relative Spread (Percentile):** 9.7 (This indicates JNJ's underperformance is near the lower end of its historical range relative to the S&P 500.)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the observed period. The relative spread percentile suggests this level of underperformance is not uncommon based on the historical data provided.

**1.2. Alpha & Beta Analysis (Periodic):**

| Year       | CAGR     | MDD   | Alpha    | Beta | Cap (B) |
|------------|----------|-------|----------|------|---------|
| 2015-2017  | 28.0%    | 56.1% | -1.0%    | -0.0 | 336.4   |
| 2016-2018  | 8.0%     | 56.6% | -10.0%   | 0.0  | 310.7   |
| 2017-2019  | 18.0%    | 56.6% | -12.0%   | 0.7  | 351.2   |
| 2018-2020  | 12.0%    | 59.2% | -8.0%    | 0.3  | 378.9   |
| 2019-2021  | 32.0%    | 59.6% | -16.0%   | 0.2  | 411.9   |
| 2020-2022  | 7.0%     | 61.4% | 5.0%     | 0.2  | 425.3   |
| 2021-2023  | -15.0%   | 61.4% | -33.0%   | 0.4  | 377.4   |
| 2022-2024  | -35.0%   | 61.4% | -61.0%   | 0.3  | 348.2   |
| 2023-2025  | 3.0%     | 70.1% | -48.0%   | 0.2  | 426.1   |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate (CAGR) has varied considerably over the periods, with significant downturns in recent periods (2021-2025).
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant potential losses from peak to trough within each period.
*   **Alpha:** Alpha is generally negative, meaning the stock has underperformed its benchmark (likely the S&P 500) on a risk-adjusted basis in most periods.  The recent Alpha values are particularly concerning.
*   **Beta:** Beta is low, indicating lower volatility than the overall market.

**2. Recent Price Action**

*   **Current Price:** 176.9499
*   **Last Market Data:** Price: 176.935, Previous Close: 178.06, Change: -0.63 (Indicates a slight downward movement)
*   **5-Day Moving Average:** 176.57
*   **20-Day Moving Average:** 175.547
*   **60-Day Moving Average:** 164.4095

**Analysis:**

*   The price is slightly above the 5-day and 20-day moving averages, suggesting a short-term upward trend. However, the price is significantly above the 60-day moving average, suggesting a longer-term upward trend. The slight negative change in the last market data suggests a minor pullback.

**3. Technical Indicators & Risk Assessment**

*   **Market Risk Indicator (MRI):** 0.3403 (Low Risk)
*   **RSI:** 65.25 (Approaching overbought territory)
*   **PPO:** -0.3592
*   **Hybrid Signal:** cash_66%_Sell 6.1% of holdings (21 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 66% on 2025-09-02)
*   **20-Day Relative Spread Change:** -3.9 (Negative: Short-term decrease)
*   **Expected Return (%):** -296.9 (Significant underperformance vs. S&P 500)

**Analysis:**

*   **MRI:** The MRI indicates low market risk.
*   **RSI:** The RSI is approaching overbought territory, suggesting the stock may be due for a pullback.
*   **PPO:** The PPO is negative, indicating the short-term moving average is below the long-term moving average, signaling a potential downward trend.
*   **Hybrid Signal:** The hybrid signal recommends selling a small portion of holdings and maintaining a high cash position, reflecting caution. It also suggests a small monthly investment, possibly for dollar-cost averaging.
*   **Relative Spread Change:** The negative change in relative spread confirms short-term underperformance compared to the S&P 500.
*   **Expected Return:** The very low expected return suggests significant potential underperformance compared to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **2025-09-02:** Johnson & Johnson (JNJ) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-09-03:** Analysts are discussing Johnson & Johnson's (JNJ) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-08-31:** Johnson & Johnson (JNJ)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-09-01:** Market experts highlight both risks and opportunities for Johnson & Johnson (JNJ), advising investors to monitor recent news and company announcements.

**Analysis:**

The news indicates JNJ is currently experiencing significant events impacting its stock performance, including volatility, analyst discussions, and potential business or regulatory changes. Monitoring company announcements and industry trends is crucial.

**5. Recent Earnings Analysis**

| 날짜        | EPS  | 매출        |
| ----------- | ---- | ----------- |
| 2025-07-24  | 2.3  | 23.74 B$    |
| 2025-04-23  | 4.57 | 21.89 B$    |
| 2024-10-23  | 1.12 | 22.47 B$    |
| 2024-07-25  | 1.95 | 22.45 B$    |
| 2025-07-24  | 1.95 | 22.45 B$    |

**Analysis:**

*   The table presents recent quarterly earnings per share (EPS) and revenue figures.  EPS has fluctuated.  Revenue shows some variation but appears relatively stable overall. The duplicated date likely indicates an error in the data.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE   |
|--------------|-------------|-------|
| 2025-06-30   | $78.47B     | 7.06% |
| 2025-03-31   | $78.11B     | 14.08%|
| 2024-12-31   | $71.49B     | 4.80% |
| 2024-09-30   | $70.16B     | 3.84% |
| 2024-06-30   | $71.54B     | 6.55% |

**Analysis:**

*   **Revenue:** Revenue has shown some growth.
*   **Profit Margin:** Profit margins are very high, suggesting strong operational efficiency. There is a slight decrease in recent quarters.
*   **Equity:**  Equity has generally increased.
*   **ROE:** Return on Equity (ROE) has fluctuated, but is trending upward in the most recent quarters.

**7. Summary and Conclusion**

Johnson & Johnson (JNJ) exhibits a mixed picture based on the provided data.

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the analyzed period, and the expected return indicates this trend could continue.
*   **Technicals:** While the price is above its short-term moving averages, the RSI suggests it might be approaching overbought territory. The PPO indicates a potential downward trend.
*   **Financials:**  The company maintains strong revenue, very high profit margins, and increasing equity. However, recent declines in profit margin and ROE should be monitored.
*   **News:** Recent news points to ongoing business developments, regulatory changes, or market events that are causing volatility in JNJ's stock price.

**Overall:** While JNJ demonstrates financial strength and stability, its underperformance relative to the market and cautionary technical signals warrant careful consideration. Investors should closely monitor company announcements, industry trends, and the impact of recent events on JNJ's future performance. The hybrid signal's recommendation to trim holdings and maintain a high cash position reflects the current uncertainties.
